Dengue Vaccine Market Report 2026

Dengue Vaccine Market Overview

• Dengue Vaccine market size has reached to $0.51 billion in 2025 • Expected to grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 17.3% • Growth Driver: Surge In Dengue Fever Cases Fuels Growth In The Dengue Vaccine Market • Market Trend: Phase 3 Trial Targets Long-Lasting Protection Against All Dengue Serotypes • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

The key promising market opportunities in the dengue vaccine market include: • Live Attenuated Vaccine (Segmentation By Type) → Expected gain of $610.71 Million • Parenteral (Segmentation By Route Of Administration) → Expected gain of $601.52 Million • Hospitals (Segmentation By End-User) → Expected gain of $390.4 Million

What Is Covered Under Dengue Vaccine Market?

A dengue vaccine is a biological preparation designed to prevent dengue fever, a mosquito-borne viral disease caused by the dengue virus (DENV). If exposed in the future, dengue Vaccines stimulate the body's immune system to recognize and fight off the dengue virus. The main types of dengue vaccines are live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid-based vaccine. Live-attenuated vaccines use a weakened virus to trigger an immune response, preparing the body to combat dengue without causing the disease. It includes different vaccine phases, such as phase I, phase II, and phase III, with treatment including diuretics, anti-allergics, blood thinners, and others. It is administered through several routes of administration, such as oral, parenteral, and others, and used by end-user hospitals, clinics, government institutes, non-governmental organizations, and others.

What Is The Dengue Vaccine Market Growth Forecast?

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to expansion of immunization programs, increasing investment in vaccine research, rising healthcare spending in endemic countries, growing focus on multi-strain vaccine efficacy, accelerated regulatory approvals. Major trends in the forecast period include rising global focus on dengue prevention, increasing government-led vaccination programs, growing adoption of tetravalent dengue vaccines, expansion of public health funding in endemic regions, rising demand for pediatric immunization solutions.

What Is Driver Of The Dengue Vaccine Market?

The rising number of dengue fever cases is expected to propel the growth of the dengue vaccine markets going forward. Dengue fever is a viral infection spread by Aedes aegypti mosquitoes, causing high fever, headaches, joint pain, and rashes. The rise in dengue fever cases is due to climate change, urbanization, inadequate mosquito control, and viral evolution. The dengue vaccine works by activating the immune system to identify and combat the dengue virus. It lessens infection severity and reduces the risk of severe complications, helping to decrease cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the rising number of dengue fever cases is driving the growth of the dengue vaccine industry.

How Will The Drivers Impact Growth In The Global Dengue Vaccine Market?

• Increasing Healthcare Expenditure (High) – The increasing healthcare expenditure will become a key driver of growth in the dengue vaccine market by 2030. Increased healthcare budgets in dengue-endemic regions drive vaccine development, distribution, and public health initiatives. Greater funding enhances public awareness, accelerates R&D and improves healthcare infrastructure, making vaccines more accessible. This boosts market growth, supports immunization programs and ensures broader vaccine availability, benefiting at-risk populations. As a result, the increasing healthcare expenditure is anticipated to contributing to annual growth in the market. • Strong Economic Growth In Emerging Markets (High) – The strong economic growth in emerging markets will emerge as a major factor driving the expansion of the dengue vaccine market by 2030. As emerging markets experience economic growth, both individuals and governments gain increased purchasing power, enhancing access to healthcare services such as vaccines. This enables national healthcare programs to allocate budgets for vaccines, effectively lowering financial barriers for the population. Governments and health authorities are increasingly prioritizing dengue vaccination initiatives to mitigate the economic impact of outbreaks. Consequently, the strong economic growth in emerging markets is projected to contributing to annual growth in the market. • Favorable Government Initiatives (High) – The favorable government initiatives within digital manufacturing processes will serve as a key growth catalyst for the dengue vaccine market by 2030. Governments implement the public health initiatives that offer vaccines at low or no cost to high-risk groups, such as children and residents of endemic areas. This approach stimulates demand and creates a reliable market for vaccines. In addition, partnerships with global health organizations like the World Health Organization (WHO) can facilitate vaccine development and distribution. These collaborations ensure that vaccines reach regions with high dengue incidence, helping to curb the disease's spread. Therefore, the favorable government initiatives is projected to supporting to annual growth in the market. • Increasing Number Of Population (Medium) – The increasing population will become a significant driver contributing to the growth of the dengue vaccine market by 2030. The growing population is contributing to more individuals residing in regions susceptible to dengue, thereby increasing the demand for preventive measures. As dengue cases rise, there is a surge in the need for vaccines to safeguard against the disease. As the need for disease protection, such as against dengue, grows, governments and healthcare systems are increasingly prioritizing mass vaccination efforts. This focus is expected to drive a significant rise in demand for dengue vaccines. Consequently, the increasing population is projected to contributing to annual growth in the market.

How Will The Restraints Impact Growth In The Global Dengue Vaccine Market?

• Economic Constraints (High) – Economic Constraints will restrict the growth of the Dengue Vaccine market during the forecast period. Dengue vaccine procurement is often dependent on government budgets and public health funding. Economic constraints can limit the ability of countries to purchase and distribute vaccines, particularly in developing regions where dengue is most prevalent. Budget limitations may result in delayed implementation of vaccination programs and reduced market volumes.

Key Players In The Global Dengue Vaccine Market

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Global Dengue Vaccine Market Trends and Insights

Major companies operating in the dengue vaccine market are focused on conducting clinical trials to develop innovative formulations such as live attenuated vaccines to provide broad, long-lasting protection against all four dengue virus serotypes. Live attenuated vaccines are made from a weakened form of the virus that cannot cause disease in healthy individuals but stimulates the immune system to develop strong, long-lasting, and broad protection, enabling the body to recognize and fight the real virus effectively if exposed in the future. For instance, in June 2025, Merck & Co. Inc., a US-based pharmaceutical company, initiated the MOBILIZE-1 Phase 3 clinical trial to evaluate V181, its investigational live attenuated quadrivalent dengue vaccine. The study aims to enroll approximately 12,000 healthy children and adolescents aged 2 to 17 in dengue-endemic countries across the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam. The trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, immunogenicity, and efficacy of a single dose of V181 against all four dengue virus serotypes, regardless of prior dengue exposure. The vaccine targets symptomatic dengue of any severity, including severe forms that may require hospitalization, and seeks to provide broad, long-lasting protection to reduce the global burden of this rapidly spreading mosquito-borne disease.

What Are Latest Mergers And Acquisitions In The Dengue Vaccine Market? Takeda Partnered With Biological E. Limited To Boost Dengue Vaccine Production And Accessibility

In February 2024, Takeda Pharmaceutical Company, a Japan-based manufacturer of dengue vaccine, partnered with Biological E. Limited. Through this collaboration, Takeda aims to accelerate the production and accessibility of the dengue vaccine QDENGA (TAK-003) in endemic regions by increasing manufacturing capacity and providing multi-dose vials to support national immunization programs. Biological E. Limited is an India-based biotechnology and biopharmaceutical company specializing in producing and supplying vaccines and therapeutics.

What Defines the Dengue Vaccine Market?

The dengue vaccine market consists of revenues earned by entities by providing treatment such as chlorothiazide, chlorthalidone, hydrochlorothiazide, and fexofenadine. The market value includes the value of related goods sold by the service provider or included within the service offering. The dengue vaccine market also includes sales of diagnostic kits, combination vaccines, clinical trial products, and post-vaccination monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dengue Vaccine Market Report 2026?

The dengue vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dengue vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.